Bismuth subsalicylate, metronidazole, and tetracycline Side Effects
Please note - some side effects for Bismuth subsalicylate, metronidazole, and tetracycline may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Side Effects by Body System - for Healthcare Professionals
Applies to: oral kit
Cardiovascular side effects have rarely included flattening of the T-wave in electrocardiographic tracings.
Gastrointestinal side effects have been reported the most frequently, but rarely led to discontinuation of therapy. These have included nausea, diarrhea, abdominal pain, melena, constipation, vomiting, discolored tongue, dyspepsia, stool abnormality, duodenal ulcer, taste perversion, flatulence, GI hemorrhage, anal discomfort, dry mouth, dysphagia, eructation, GI monilia, glossitis, intestinal obstruction, rectal hemorrhage, and stomatitis. A sharp, unpleasant metallic taste is not unusual with the use of metronidazole.
A furry tongue, glossitis, stomatitis have been reported during therapy with metronidazole. These may be associated with a sudden overgrowth of Candida which may occur during therapy.
Rare instances of esophagitis and esophageal ulceration have been reported in patients taking the tetracycline-class antibiotics. In most of these cases, the patient took the medication immediately before going to bed.
The darkening of the tongue associated with the use of bismuth subsalicylate is considered a temporary and harmless adverse reaction.
Dermatologic side effects have been reported rarely. These have included acne, ecchymosis, photosensitivity reaction, pruritus, and rash. Maculopapular and erythematous rashes have been reported with the use of tetracyclines. Exfoliative dermatitis, photosensitivity, onycholysis, and discoloration of the nails have also been reported rarely.
Other side effects have rarely included flu syndrome, infection, malaise, neoplasm, syncope, and tooth disorder.
Respiratory side effects have included upper respiratory infection, sinusitis, and rhinitis.
Ocular side effects have rarely included conjunctivitis.
Metabolic side effects have rarely included increases in SGOT and SGPT.
Musculoskeletal side effects have included asthenia, arthritis, rheumatoid arthritis, and tendonitis. Enamel hypoplasia has been reported with the use of tetracyclines.
Persistent peripheral neuropathy has been reported in some patients receiving prolonged administration of metronidazole. Patients should be warned to stop treatment and to consult with their doctor if numbness or paresthesia of an extremity occurs.
Nervous system side effects have rarely included nervousness, dizziness, insomnia, and somnolence. Pseudotumor cerebri and myasthenic syndrome have been reported rarely with the use of tetracyclines. Two serious side effects reported with the use of metronidazole have been convulsive seizures and peripheral neuropathy. Patients should be advised to stop treatment and consult with their physicians if any neurologic symptoms occur.
Hematologic side effects have included reversible neutropenia (leukopenia) with the use of metronidazole. Reversible thrombocytopenia has also been reported rarely. Hemolytic anemia, thrombocytopenia, thrombocytopenia purpura, neutropenia, and eosinophilia have been reported with the use of tetracyclines.
Tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland when used over long periods. Thyroid function studies are reported to remain normal.
Hepatic side effects have included hepatotoxicity and liver failure in patients receiving large doses of tetracyclines. Increases in liver enzymes and hepatic toxicity has been reported rarely in patients with renal impairment treated with tetracyclines.
Hypersensitivity side effects have included urticaria, erythematous rash, flushing, nasal congestion, dryness of mouth (or vagina or vulva), and fever with the use of metronidazole. Angioneurotic edema, anaphylaxis, anaphylactoid purpura, pericarditis, exacerbation of systemic lupus erythematosus, urticaria, and serum sickness-like reactions, as fever, rash and arthralgia have been reported with the use of tetracyclines.
Instances of darkening of the urine have been reported by approximately one patient in 100,000. It is believed a metabolite of metronidazole, with no clinical significance, is responsible for this rare occurrence.
Renal side effects have included urinary tract infection. Dysuria, cystitis, polyuria, incontinence, and a sense of pelvic pressure have been reported with the use of metronidazole. Darkening of the urine has been reported rarely. Rise in BUN has been reported with the use of tetracyclines.Top
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.